December 20, 2016 07:20 AM EST

Akebia forges $1B US pact with Otsuka on lead drug for CKD, shares spike

John Carroll

Editor & Founder

Akebia $AKBA has struck a landmark $1 billion partnership with Otsuka for its late-stage drug vadadustat, an oral treatment for anemia related to chronic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Akebia forges $1B US pact with Otsuka on lead drug for CKD, shares spike

John Carroll

Editor & Founder

Sign up to read this article for free.

A look at biotech's year of the megaround

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Neumora's major depression drug flunks first of three Phase 3 trials

Regeneron buys London-based ocular biotech

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Ake­bia forges $1B US pact with Ot­su­ka on lead drug for CKD, shares spike

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Re­gen­eron buys Lon­don-based oc­u­lar biotech

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Akebia forges $1B US pact with Otsuka on lead drug for CKD, shares spike

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Neumora's major depression drug flunks first of three Phase 3 trials

Regeneron buys London-based ocular biotech

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?